Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report on May 5, 2006, primarily to furnish a press release dated May 3, 2006. This press release details the company's financial and operating results for the first quarter ended March 31, 2006. Investors should refer to the press release (Exhibit 99(a)) for specific performance metrics and financial condition updates for the period. The filing itself does not contain the detailed financial results but directs stakeholders to the attached press release. Therefore, any analysis of the company's performance for the first quarter of 2006 will need to be derived from the content of that press release.
Key Highlights
- 1The 8-K filing primarily serves to furnish a press release announcing Q1 2006 financial and operating results.
- 2The press release was issued on May 3, 2006, and is attached as Exhibit 99(a).
- 3The report covers the financial and operational performance for the quarter and three months ended March 31, 2006.
- 4Investors seeking detailed financial performance data for the period must consult the attached press release.
- 5The filing itself contains minimal operational or financial detail, acting as a notification of the press release.
- 6Key information for investors would be the actual financial numbers and operational updates contained within the press release.